Salicylate clearance, the resultant of protein binding and metabolism
- PMID: 466931
- DOI: 10.1002/cpt1979263380
Salicylate clearance, the resultant of protein binding and metabolism
Abstract
Steady-state plasma salicylate concentrations and protein binding were examined in 9 normal subjects to determine relationships among daily dose, total and unbound salicylate concentrations, and total and unbound clearances. Aspirin doses ranging from 0.66 to 4.0 mg/kg/hr were given to steady state. Free and total salicylate concentrations were measured with spectrophotometric, fluorimetric, and equilibrium dialysis techniques. Although unbound clearance decreased over the therapeutic range, total clearance was unchanged. The former is a consequence of saturable metabolism; the latter, of saturable plasma protein binding as well as saturable metabolism. The fraction unbound increased linearly with unbound concentration. Clearance determined at 1.8 mg/kg/hr was used to predict levels obtained at higher aspirin doses. Analysis of residuals was used to ascertain the accuracy of the prediction. The coefficient of variation from prediction among subjects was found to be +/- 14%. It is concluded that, in normal subjects, salicylate clearance changes relatively little over the therapeutic range because the increasing fraction unbound compensates for decreasing clearance of unbound drug.
Similar articles
-
Clinical pharmacokinetics of the salicylates.Clin Pharmacokinet. 1985 Mar-Apr;10(2):164-77. doi: 10.2165/00003088-198510020-00004. Clin Pharmacokinet. 1985. PMID: 3888490 Review.
-
Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.J Pharmacokinet Biopharm. 1991 Oct;19(5):575-95. doi: 10.1007/BF01062964. J Pharmacokinet Biopharm. 1991. PMID: 1783992
-
Concentration dependent plasma protein binding of salicylate in rheumatoid patients.Clin Pharmacokinet. 1979 Mar-Apr;4(2):137-43. doi: 10.2165/00003088-197904020-00006. Clin Pharmacokinet. 1979. PMID: 378501 Clinical Trial.
-
Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers.Br J Clin Pharmacol. 1989 Dec;28(6):695-702. doi: 10.1111/j.1365-2125.1989.tb03562.x. Br J Clin Pharmacol. 1989. PMID: 2611090 Free PMC article. Clinical Trial.
-
Protein binding in antiretroviral therapies.AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35. doi: 10.1089/088922203769232629. AIDS Res Hum Retroviruses. 2003. PMID: 14585213 Review.
Cited by
-
Nonlinear pharmacokinetics: clinical Implications.Clin Pharmacokinet. 1991 Jun;20(6):429-46. doi: 10.2165/00003088-199120060-00001. Clin Pharmacokinet. 1991. PMID: 2044328 Review.
-
Clinical pharmacokinetics of the salicylates.Clin Pharmacokinet. 1985 Mar-Apr;10(2):164-77. doi: 10.2165/00003088-198510020-00004. Clin Pharmacokinet. 1985. PMID: 3888490 Review.
-
Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.J Pharmacokinet Biopharm. 1991 Oct;19(5):575-95. doi: 10.1007/BF01062964. J Pharmacokinet Biopharm. 1991. PMID: 1783992
-
Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease.Eur J Clin Pharmacol. 1983;25(2):253-61. doi: 10.1007/BF00543800. Eur J Clin Pharmacol. 1983. PMID: 6628510
-
Salicylate intoxication in the elderly. Recognition and recommendations on how to prevent it.Drugs Aging. 1992 Jan-Feb;2(1):20-34. doi: 10.2165/00002512-199202010-00004. Drugs Aging. 1992. PMID: 1554971 Review.